hRPC for Retinitis Pigmentosa
(hRPCRP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new cell therapy called hRPC, designed to assist individuals with retinitis pigmentosa, a condition that leads to vision loss. The primary goal is to determine if a single injection of these cells is safe and well-tolerated in those with significant vision impairment due to this condition. Suitable candidates have been diagnosed with retinitis pigmentosa and experience low vision in at least one eye. Researchers will monitor participants for two years to assess safety and any potential vision improvement. As a Phase 1/Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you have used systemic immunosuppressive agents (like corticosteroids) in the 6 months before treatment.
Is there any evidence suggesting that hRPC is likely to be safe for humans?
Research has shown that special cells called human retinal progenitor cells (hRPC) might help treat retinitis pigmentosa, a condition that leads to vision loss. In earlier studies, researchers safely injected these cells into the eye. One study confirmed the long-term safety of this treatment, suggesting it could help repair vision. Although this information is still early, it offers hope that hRPC could be a safe treatment for people with this condition. The current trial aims to further assess the safety of hRPC. Participants will receive one injection and be monitored for two years to ensure the treatment's safety.12345
Why do researchers think this study treatment might be promising?
Unlike standard treatments for retinitis pigmentosa, which often focus on managing symptoms or slowing the disease's progress, the hRPC treatment uses human retinal progenitor cells. This approach is exciting because it aims to replace damaged retinal cells and potentially restore vision, rather than just slow down its loss. The delivery method is also unique, involving a direct subretinal injection, which allows the cells to integrate directly into the retina. Researchers are optimistic about this treatment because it represents a regenerative approach, offering hope for improved vision and quality of life.
What evidence suggests that hRPC might be an effective treatment for retinitis pigmentosa?
Research has shown that human retinal progenitor cells (hRPC) might improve vision in some individuals with retinitis pigmentosa. In this trial, participants will receive a single subretinal administration of hRPC. Studies have found that hRPC can enhance vision clarity in some patients, particularly with higher doses. Early results indicate that these cells are safe and might help repair vision loss over time. Although further research is necessary, the initial findings are promising for hRPC as a potential treatment option.13456
Who Is on the Research Team?
Jason Comander, MD
Principal Investigator
Massachusetts Eye and Ear Infirmary (MEEI)
Vince Holmes
Principal Investigator
ReNeuron Limited
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single subretinal injection of hRPC cells in one eye
Follow-up
Participants are monitored for safety and tolerability, with detailed ophthalmic examinations and imaging
What Are the Treatments Tested in This Trial?
Interventions
- hRPC
Find a Clinic Near You
Who Is Running the Clinical Trial?
ReNeuron Limited
Lead Sponsor